Full Text
The Full Text of this article is available as a PDF (98.7 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M. B., Hawkey C. J., Hochberg M. C. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528. doi: 10.1056/NEJM200011233432103. [DOI] [PubMed] [Google Scholar]
- FitzGerald G. A., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001 Aug 9;345(6):433–442. doi: 10.1056/NEJM200108093450607. [DOI] [PubMed] [Google Scholar]
- Mukherjee D., Nissen S. E., Topol E. J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001 Aug 22;286(8):954–959. doi: 10.1001/jama.286.8.954. [DOI] [PubMed] [Google Scholar]
- Sanmuganathan P. S., Ghahramani P., Jackson P. R., Wallis E. J., Ramsay L. E. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart. 2001 Mar;85(3):265–271. doi: 10.1136/heart.85.3.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Silverstein F. E., Faich G., Goldstein J. L., Simon L. S., Pincus T., Whelton A., Makuch R., Eisen G., Agrawal N. M., Stenson W. F. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000 Sep 13;284(10):1247–1255. doi: 10.1001/jama.284.10.1247. [DOI] [PubMed] [Google Scholar]